PMID: 7581360Aug 1, 1995Paper

Expression of human full-length and minidystrophin in transgenic mdx mice: implications for gene therapy of Duchenne muscular dystrophy

Human Molecular Genetics
Dominic J WellsGeorge Dickson

Abstract

Duchenne muscular dystrophy (DMD) is a lethal X-linked recessive disorder with a high spontaneous mutation rate and no effective treatment, hence development of genetic based therapies is an important goal. We report that expression of a recombinant human minidystrophin cDNA, compatible with current viral vectors, can significantly reduce the myopathic phenotype in transgenic mdx mice, even when expressed at only 20-30% of endogenous dystrophin levels at the sarcolemma. To the extent that data obtained in mouse studies are applicable to DMD, the virtual elimination of morphological and biochemical abnormalities in the mdx mouse supports the use of this cDNA in somatic gene therapy protocols for DMD.

Citations

Sep 1, 1996·Brain & Development·K InuiG Dickson
Jun 11, 2002·Biochemical and Biophysical Research Communications·Miki SakamotoShin'ichi Takeda
Sep 11, 2002·Neuromuscular Disorders : NMD·Dominic J Wells, Kim E Wells
Sep 11, 2002·Neuromuscular Disorders : NMD·G DicksonS A Fabb
Sep 11, 2002·Neuromuscular Disorders : NMD·Annemieke Aartsma-RusJudith C T van Deutekom
Nov 26, 2003·Lancet Neurology·Francesco MuntoniAlessandra Ferlini
Jun 12, 2008·Molecular Therapy : the Journal of the American Society of Gene Therapy·Natee JearawiriyapaisarnRyszard Kole
Sep 4, 2008·Molecular Therapy : the Journal of the American Society of Gene Therapy·Helen FosterGeorge Dickson
Sep 9, 2010·Molecular Therapy : the Journal of the American Society of Gene Therapy·Yoshitsugu AokiShin'ichi Takeda
Oct 7, 2010·Molecular Therapy : the Journal of the American Society of Gene Therapy·Paul S SharpDominic J Wells
Apr 7, 2011·Molecular Therapy : the Journal of the American Society of Gene Therapy·Christophe PichavantJacques P Tremblay
Apr 16, 1996·Proceedings of the National Academy of Sciences of the United States of America·N DeconinckJ M Gillis
Jul 1, 1996·The Journal of Cell Biology·J A RafaelJ S Chamberlain
Aug 1, 1996·The Journal of Experimental Medicine·D S ChaoD S Bredt
Sep 22, 2006·Human Molecular Genetics·Dongsheng Duan
Mar 19, 2009·ILAR Journal·Zejing WangRainer Storb
Aug 1, 2009·Development, Growth & Differentiation·Morris BeshayRalph A Schmid
Aug 19, 2011·Science Translational Medicine·Francesco Saverio TedescoGiulio Cossu
May 5, 2005·Blood·Mehrdad AbediPeter J Quesenberry
Feb 18, 2011·Journal of Cell Science·Kurt W PrinsJames M Ervasti
Oct 18, 2001·BioDrugs : Clinical Immunotherapeutics, Biopharmaceuticals and Gene Therapy·S Takeda, Y Miyagoe-Suzuki
Mar 6, 2013·FASEB Journal : Official Publication of the Federation of American Societies for Experimental Biology·Maaike van PuttenAnnemieke M Aartsma-Rus
Jun 25, 2016·Expert Opinion on Orphan Drugs·Yongping YueDongsheng Duan
Feb 12, 2008·Biochimica Et Biophysica Acta·Sébastien LegardinierElisabeth Le Rumeur
Sep 11, 2007·Neuromuscular Disorders : NMD·Marcella NeriFrancesco Muntoni
Oct 13, 2011·The Journal of Pathology·Virginie Carmignac, Madeleine Durbeej
Mar 31, 2015·Annals of Clinical and Translational Neurology·Patricia C SondergaardLouise R Rodino-Klapac
Jul 30, 2005·Neuromuscular Disorders : NMD·Patrick Reed, Robert J Bloch
Jan 10, 2012·Journal of Molecular Biology·Davin M HendersonJames M Ervasti

❮ Previous
Next ❯

Related Concepts

Related Feeds

CREs: Gene & Cell Therapy

Gene and cell therapy advances have shown promising outcomes for several diseases. The role of cis-regulatory elements (CREs) is crucial in the design of gene therapy vectors. Here is the latest research on CREs in gene and cell therapy.